vs
Fifth Third Bancorp（FITB）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Fifth Third Bancorp的季度营收约是Revvity的2.0倍（$1.5B vs $772.1M），Fifth Third Bancorp净利率更高（47.7% vs 12.7%，领先35.0%），Fifth Third Bancorp同比增速更快（6.4% vs 5.9%），Fifth Third Bancorp自由现金流更多（$765.0M vs $161.8M）
Fifth Third Bancorp是总部位于美国俄亥俄州辛辛那提的银行控股集团，为美国大型银行之一，位列《财富》美国500强第321位。旗下银行在全美12个州共运营1087家分行及2400台自动柜员机，服务覆盖多区域市场。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FITB vs RVTY — 直观对比
营收规模更大
FITB
是对方的2.0倍
$772.1M
营收增速更快
FITB
高出0.5%
5.9%
净利率更高
FITB
高出35.0%
12.7%
自由现金流更多
FITB
多$603.2M
$161.8M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $772.1M |
| 净利润 | $730.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 59.7% | 14.5% |
| 净利率 | 47.7% | 12.7% |
| 营收同比 | 6.4% | 5.9% |
| 净利润同比 | 17.7% | 3.9% |
| 每股收益（稀释后） | $1.03 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FITBRVTY
| Q4 25 | $1.5B | $772.1M | ||
| Q3 25 | $1.5B | $698.9M | ||
| Q2 25 | $1.5B | $720.3M | ||
| Q1 25 | $1.4B | $664.8M | ||
| Q4 24 | $1.4B | $729.4M | ||
| Q3 24 | — | $684.0M | ||
| Q2 24 | — | $691.7M | ||
| Q1 24 | — | $649.9M |
净利润FITBRVTY
| Q4 25 | $730.0M | $98.4M | ||
| Q3 25 | $649.0M | $46.7M | ||
| Q2 25 | $628.0M | $53.9M | ||
| Q1 25 | $515.0M | $42.2M | ||
| Q4 24 | $620.0M | $94.6M | ||
| Q3 24 | — | $94.4M | ||
| Q2 24 | — | $55.4M | ||
| Q1 24 | — | $26.0M |
毛利率FITBRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率FITBRVTY
| Q4 25 | 59.7% | 14.5% | ||
| Q3 25 | 55.1% | 11.7% | ||
| Q2 25 | 54.0% | 12.6% | ||
| Q1 25 | 45.4% | 10.9% | ||
| Q4 24 | 53.3% | 16.3% | ||
| Q3 24 | — | 14.3% | ||
| Q2 24 | — | 12.4% | ||
| Q1 24 | — | 6.8% |
净利率FITBRVTY
| Q4 25 | 47.7% | 12.7% | ||
| Q3 25 | 42.7% | 6.7% | ||
| Q2 25 | 42.0% | 7.5% | ||
| Q1 25 | 35.8% | 6.4% | ||
| Q4 24 | 43.1% | 13.0% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | — | 8.0% | ||
| Q1 24 | — | 4.0% |
每股收益（稀释后）FITBRVTY
| Q4 25 | $1.03 | $0.86 | ||
| Q3 25 | $0.91 | $0.40 | ||
| Q2 25 | $0.88 | $0.46 | ||
| Q1 25 | $0.71 | $0.35 | ||
| Q4 24 | $0.85 | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $13.6B | — |
| 股东权益账面价值 | $21.7B | $7.3B |
| 总资产 | $214.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.63× | — |
8季度趋势，按日历期对齐
现金及短期投资FITBRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务FITBRVTY
| Q4 25 | $13.6B | — | ||
| Q3 25 | $13.7B | — | ||
| Q2 25 | $14.5B | — | ||
| Q1 25 | $14.5B | — | ||
| Q4 24 | $14.3B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益FITBRVTY
| Q4 25 | $21.7B | $7.3B | ||
| Q3 25 | $21.1B | $7.4B | ||
| Q2 25 | $21.1B | $7.6B | ||
| Q1 25 | $20.4B | $7.6B | ||
| Q4 24 | $19.6B | $7.7B | ||
| Q3 24 | — | $7.9B | ||
| Q2 24 | — | $7.9B | ||
| Q1 24 | — | $7.8B |
总资产FITBRVTY
| Q4 25 | $214.4B | $12.2B | ||
| Q3 25 | $212.9B | $12.1B | ||
| Q2 25 | $210.0B | $12.4B | ||
| Q1 25 | $212.7B | $12.4B | ||
| Q4 24 | $212.9B | $12.4B | ||
| Q3 24 | — | $12.8B | ||
| Q2 24 | — | $13.4B | ||
| Q1 24 | — | $13.4B |
负债/权益比FITBRVTY
| Q4 25 | 0.63× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | 0.73× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $929.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $765.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 50.0% | 21.0% |
| 资本支出强度资本支出/营收 | 10.7% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.27× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $3.9B | $509.4M |
8季度趋势，按日历期对齐
经营现金流FITBRVTY
| Q4 25 | $929.0M | $182.0M | ||
| Q3 25 | $1.0B | $138.5M | ||
| Q2 25 | $1.3B | $134.3M | ||
| Q1 25 | $1.2B | $128.2M | ||
| Q4 24 | $-101.0M | $174.2M | ||
| Q3 24 | — | $147.9M | ||
| Q2 24 | — | $158.6M | ||
| Q1 24 | — | $147.6M |
自由现金流FITBRVTY
| Q4 25 | $765.0M | $161.8M | ||
| Q3 25 | $886.0M | $120.0M | ||
| Q2 25 | $1.2B | $115.5M | ||
| Q1 25 | $1.1B | $112.2M | ||
| Q4 24 | $-246.0M | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率FITBRVTY
| Q4 25 | 50.0% | 21.0% | ||
| Q3 25 | 58.3% | 17.2% | ||
| Q2 25 | 77.8% | 16.0% | ||
| Q1 25 | 77.7% | 16.9% | ||
| Q4 24 | -17.1% | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度FITBRVTY
| Q4 25 | 10.7% | 2.6% | ||
| Q3 25 | 10.5% | 2.6% | ||
| Q2 25 | 9.6% | 2.6% | ||
| Q1 25 | 8.1% | 2.4% | ||
| Q4 24 | 10.1% | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率FITBRVTY
| Q4 25 | 1.27× | 1.85× | ||
| Q3 25 | 1.61× | 2.97× | ||
| Q2 25 | 2.08× | 2.49× | ||
| Q1 25 | 2.39× | 3.03× | ||
| Q4 24 | -0.16× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FITB
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
